Phenytoin: the pseudosteady-state phenomenon

Area of Science:

• Pharmacokinetics
• Clinical Neurology
• Epilepsy Management

Background:

• Plasma phenytoin levels can unexpectedly change after achieving a steady state, termed pseudosteady state.
• This phenomenon can impact seizure control and medication toxicity.
• Understanding pseudosteady state is crucial for optimizing phenytoin therapy.

Purpose of the Study:

• To investigate the characteristics and duration of pseudosteady state periods in patients with complex partial seizures.
• To analyze the timing and triggers of pseudosteady state onset and resolution.
• To correlate plasma phenytoin level fluctuations during pseudosteady state with clinical outcomes.

Main Methods:

• Evaluation of 13 pseudosteady state periods in 10 inpatients.
• Analysis of phenytoin dosage changes and drug withdrawal as potential triggers.
• Monitoring of plasma phenytoin levels and seizure frequency over time.

Main Results:

• Pseudosteady state occurred in 11 out of 13 instances after phenytoin dosage adjustments and in 2 after withdrawal.
• These periods began 2-12 days after dosage changes and lasted 5-10 days with stable plasma levels (+/- 5%).
• Following this, plasma levels fluctuated by >25% for 5-22 days before a final steady state was reached 13-31 days post-initiation.

Conclusions:

• Pseudosteady state represents a significant, transient period of phenytoin level instability following dosage adjustments or withdrawal.
• Fluctuations during pseudosteady state can lead to increased seizure frequency or medication toxicity.
• Careful monitoring is essential during and after phenytoin dosage modifications to manage pseudosteady state effectively.